MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

PubWeight™: 44.28‹?› | Rank: Top 0.01% | All-Time Top 1000

🔗 View Article (PMID 12114036)

Published in Lancet on July 06, 2002


Heart Protection Study Collaborative Group

Associated clinical trials:

French Registry of Acute Coronary Syndrome (Fast-MI) | NCT00673036

Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs | NCT00509717

Prevention of Ischemic Events in Patients With Peripheral Arterial Disease (PID-PAB) | NCT00761969

Virtual Histology Findings and Effects of Varying Doses of Atorvastatin Treatment (VENUS) | NCT01200056

C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS) (C2 -CORVUS) | NCT00921752

French Cohort of Myocardial Infarction Evaluation (FRENCHIE) | NCT04050956

Articles citing this

(truncated to the top 100)

A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) 19.05

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 16.52

Resuscitating clinical research in the United Kingdom. BMJ (2003) 9.19

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ (2004) 7.92

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65

Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2011) 5.30

Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30

A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet (2011) 5.23

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet (2011) 5.08

Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest (2003) 4.42

Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation (2010) 4.37

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet (2011) 4.23

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet (2010) 4.23

Prevention and early detection of vascular complications of diabetes. BMJ (2006) 4.14

Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ (2003) 3.85

The break-even point: when medical advances are less important than improving the fidelity with which they are delivered. Ann Fam Med (2005) 3.84

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet (2015) 3.75

Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med (2006) 3.71

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ (2006) 3.68

Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ (2006) 3.62

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51

Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation (2008) 3.48

Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48

Two decades of progress in preventing vascular disease. Lancet (2002) 3.30

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16

Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet (2007) 3.13

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03

Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ (2005) 3.00

Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology (2008) 2.97

Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ (2003) 2.97

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90

Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci (2009) 2.86

Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ (2005) 2.75

Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ (2010) 2.68

Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med (2008) 2.68

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ (2006) 2.67

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron (2011) 2.67

Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs (2008) 2.62

Excess weight and the risk of incident coronary heart disease among men and women. Obesity (Silver Spring) (2009) 2.56

Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54

Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract (2009) 2.40

Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med (2011) 2.40

Nonoptimal lipids commonly present in young adults and coronary calcium later in life: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Ann Intern Med (2010) 2.37

Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease--a Mendelian Randomisation study. PLoS One (2008) 2.37

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology (2011) 2.35

A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ (2007) 2.35

Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ (2011) 2.32

Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem (2009) 2.31

Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31

Insulin resistance and atherosclerosis. J Clin Invest (2006) 2.27

Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev (2014) 2.24

Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord (2007) 2.24

An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ (2010) 2.22

Rho GTPases, statins, and nitric oxide. Circ Res (2005) 2.21

LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidol (2007) 2.21

Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart (2003) 2.20

Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol (2004) 2.18

Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag (2008) 2.13

Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med (2010) 2.06

Statin use and lower extremity amputation risk in nonelderly diabetic patients. J Vasc Surg (2013) 2.05

Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ (2006) 2.03

Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol (2008) 2.03

Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02

Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ (2009) 2.02

Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start. Mayo Clin Proc (2015) 1.99

Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol (2010) 1.96

Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study. BMJ (2003) 1.94

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 1.92

Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med (2011) 1.92

Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med (2014) 1.91

The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials (2004) 1.90

Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol (2005) 1.89

Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc (2009) 1.88

Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol (2014) 1.87

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials (2007) 1.86

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J (2015) 1.83

Risk functions for prediction of cardiovascular disease in elderly Australians: the Dubbo Study. Med J Aust (2003) 1.82

Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension (2009) 1.81

MRI of carotid atherosclerosis: clinical implications and future directions. Nat Rev Cardiol (2010) 1.78

Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci U S A (2006) 1.77

Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev (2012) 1.76

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J (2012) 1.75

Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med (2015) 1.74

Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med (2007) 1.72

The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis (2011) 1.70

Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ (2008) 1.70

A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis (2014) 1.67

Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009) 1.66

The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int J Stroke (2008) 1.65

Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes (2008) 1.64

Alzheimer disease. Dis Mon (2010) 1.64

Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol (2013) 1.63

Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Intern Med (2015) 1.61

How evidence-based are the recommendations in evidence-based guidelines? PLoS Med (2007) 1.60

Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol (2011) 1.59

Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. J Am Coll Cardiol (2011) 1.58

Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc (2010) 1.58

Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J (2014) 1.57

Articles by these authors

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 13.69

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 7.41

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet (2004) 5.19

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet (2011) 4.23

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet (2005) 4.20

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation (2012) 2.90

The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med (2005) 1.44

Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes (2009) 1.07

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet (2011) 0.92